

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPRO	VAL		
OMB	3235-		
Number:	0104		
Estimated average			
burden hours pe			
response	0.5		

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *									
Person *	_			3. Issuer Name and Ticker or Trading Symbol					
	Statem		PI	PIERIS PHARMACEUTICALS, INC. [PIRS]			[PIRS]		
Prelack Steven		nth/Day/Year) 29/2015							
(Last) (First) (Mid	ldle)	29/2013		4. Relationship of Reporting				5. If Amendment, Date Original	
C/O PIERIS			Pe	Person(s) to Issuer (Check all applicable) _X_Director 10% Owner Officer (give Other (specify			Filed(Month/Day/Year)		
PHARMACEUTICALS,									
INC., LISE-MEITNER-STR.	ASSE								
30			title	e below)	below)				
(Street)							6. Individ	ual or Joint/Group	
							•	ck Applicable Line)	
FREISING-								ed by One Reporting Person ed by More than One Reporting	
WEIHENSTEPHAN, 2M 85	354						Person		
(City) (State) (Z	ip)	Tab	le I - Non	-Derivati	ve Securitie	s Ben	eficially	Owned	
1.Title of Security			mount of Se		3.			rect Beneficial	
(Instr. 4)		Beneficially ((Instr. 4)				Owner			
					Form: Direct (D) or				
					Indirect (I)				
					(Instr. 5)				
Reminder: Report on a separate lin	ne for each cl	ace of committee							
		to the collec	ction of in	formation	directly or inding the contained in contained in the cont	n this		SEC 1473 (7-02)	
not require number.	d to respor	to the collected to the	ction of in e form dis	formatior plays a c	n contained i urrently valid	n this	control		
not require number. Table II - Derivative	d to respor	to the colleged unless the control of the college o	ction of in e form dis yned (<i>e.g.</i> , p	formatior plays a co outs, calls,	n contained i urrently valid	n this	control	securities)	
not require number.	Securities B 2. Date Exe	to the collected unless the eneficially Owner cisable and	vned (e.g., p	formation plays a control play a control pla	n contained i urrently valid warrants, opt	n this d OMB	control	securities) 6. Nature of Indirect	
not require number. Table II - Derivative 1. Title of Derivative Security	d to respor	to the collected unless the eneficially Own cisable and Date	ction of in e form dis yned (<i>e.g.</i> , p	formation plays a control plays a control plays, calls, and a control plays a	n contained i urrently valid warrants, opt	ions, co	control	securities)	
not require number. Table II - Derivative 1. Title of Derivative Security	Securities B 2. Date Exe Expiration I	to the collected unless the eneficially Own cisable and Date	vned (e.g., p	formation plays a control plays a control plays, calls, and a control plays a	warrants, opt of 4. Conversi or Exerci Price of	ions, co	onvertible wnership rm of erivative	securities) 6. Nature of Indirect Beneficial Ownership	
not require number. Table II - Derivative 1. Title of Derivative Security	Securities B 2. Date Exe Expiration I	eneficially Owrcisable and Date ar)	wned (e.g., p 3. Title and Securities 1 Derivative (Instr. 4)	formation plays a control play	warrants, opt of 4. Conversi or Exerci Price of Derivativ or Security	ions, co	onvertible wnership rm of erivative curity: rect (D)	securities) 6. Nature of Indirect Beneficial Ownership	
not require number. Table II - Derivative 1. Title of Derivative Security	Securities B 2. Date Exe Expiration I (Month/Day/Ye) Date	eneficially Owrcisable and Date ar)	vned (e.g., p 3. Title and Securities 1 Derivative	formation plays a co puts, calls, d Amount of Underlying Security	warrants, opt of 4. Conversi or Exerci Price of Derivativ or Security	ions, co	onvertible wnership rm of erivative curity: rect (D) Indirect	securities) 6. Nature of Indirect Beneficial Ownership	

Reporting Owner Name / Address		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Prelack Steven						
C/O PIERIS PHARMACEUTICALS, INC.	X					
LISE-MEITNER-STRASSE 30	Λ					
FREISING-WEIHENSTEPHAN, 2M 85354						

Signatures

/s/ Marc D. Mantell, Attorney-in-fact		06/29/2015
---------------------------------------	--	------------

**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests in equal quarterly installments over a thirty-six month period, beginning on March 31, 2015.

Remarks:

Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of, Steven S. Yoder and Darlene Deptula-Hicks of Pieris Pharmaceuticals, Inc. and Anne Leland, Jacquelyn Cannata, Marc Mantell and Caroline Gammill of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents:
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact, on behalf of the undersigned pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 12th day of June, 2015.

/s/ Steven Prelack
----Steven Prelack